It’s good to see some progress on treating the awful diseases we call mesothelioma. It’s also good to see that progress followed and mentioned by others on the defense side of the litigation. On both topics, see this April 3, 2015 post from Ed Casmere and Emily Gesmundo at the Product Liability & Mass Torts Blog from Schiff Hardin. The post is about a new orphan drug, CRS-207, made by Aduro Biotech, Inc.
Kirk Hartley
Comentários